Related references
Note: Only part of the references are listed.Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban
Henrik von Horn et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2022)
Heparin Anti-Xa Activity, a Readily Available Unique Test to Quantify Apixaban, Rivaroxaban, Fondaparinux, and Danaparoid Levels
Elodie Boissier et al.
ANESTHESIA AND ANALGESIA (2021)
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
Gary H. Lyman et al.
BLOOD ADVANCES (2021)
A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation
Guido Willekens et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Executive Summary Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report
Scott M. Stevens et al.
CHEST (2021)
Venous thromboembolism associated with central venous catheters in patients with cancer: From pathophysiology to thromboprophylaxis, areas for future studies
Philippe Debourdeau et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
Nigel S. Key et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Central venous catheter-related thrombosis in children and adults
Divyaswathi Citla Sridhar et al.
THROMBOSIS RESEARCH (2020)
Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban
Damon E. Houghton et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism
Thomas L. Ortel et al.
BLOOD ADVANCES (2020)
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
A. A. Khorana et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The blood compatibility challenge. Part 1: Blood-contacting medical devices: The scope of the problem
Iqbal H. Jaffer et al.
ACTA BIOMATERIALIA (2019)
The anticoagulants rivaroxaban and low molecular weight heparin prevent PICC-related upper extremity venous thrombosis in cancer patients
Shoutian Lv et al.
MEDICINE (2019)
Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator
Paul Billoir et al.
ANNALS OF PHARMACOTHERAPY (2019)
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Marc Carrier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants
Robert C. Gosselin et al.
THROMBOSIS AND HAEMOSTASIS (2018)
A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2)
G. A. Davies et al.
THROMBOSIS RESEARCH (2018)
Discovery methods of coagulation-inhibiting drugs
Antonio Gomez-Outes et al.
EXPERT OPINION ON DRUG DISCOVERY (2017)
Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels
Lina Sabor et al.
THROMBOSIS RESEARCH (2017)
Epidemiology, diagnosis, prevention and treatment of catheter-related thrombosis in children and adults
Lisa Baumann Kreuziger et al.
THROMBOSIS RESEARCH (2017)
Rivaroxaban in the Treatment of PICC-associated Upper Extremity Venous Thrombosis
Fenling Fan et al.
CLINICAL THERAPEUTICS (2017)
Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level?
Robert C. Gosselin et al.
ANNALS OF PHARMACOTHERAPY (2015)
Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits
Jonathan W. Yau et al.
BLOOD (2014)
Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits
Jonathan W. Yau et al.
THROMBOSIS AND HAEMOSTASIS (2014)
Central venous catheter-related thrombosis
William Geerts
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2014)
Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo
Jonathan W. Yau et al.
ACTA BIOMATERIALIA (2012)
Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo
Jonathan W. Yau et al.
BLOOD (2011)
Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non-ST-Segment Elevation Acute Coronary Syndromes An Individual Patient-Level Combined Analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) Randomized Trials
Shamir R. Mehta et al.
CIRCULATION (2008)
Thromboprophylaxis in cancer patients with central venous catheters - A systematic review and meta-analysis
Pooja Chaukiyal et al.
THROMBOSIS AND HAEMOSTASIS (2008)
Venous thromboembolism associated with long-term use of central venous catheters in cancer patients
M Verso et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
